Brandon Newman, PharmD, MMHC, CSP, program director, specialty pharmacy, Vanderbilt University Medical Center, explains the benefits of collaboration between payers and academic centers and how this collaboration, in turn, benefits patients.
Brandon Newman, PharmD, MMHC, CSP, program director, specialty pharmacy, Vanderbilt University Medical Center, explains the benefits of collaboration between payers and academic centers and how this collaboration, in turn, benefits patients.
Transcript
What are the benefits of collaboration between payers and academic medical centers?
I think 1 thing, from my perspective in working for a dispensing pharmacy that’s based out of an academic medical center, is that first and foremost, we have to be able to dispense these drugs to these patients so we can follow the patients really closely. So, 1 big challenge with us is payer lockout. I think that if we can collaborate with a payer to be able to become part of that network to be able to fill for those patients, we can follow them closely, and, by following them closely, we can monitor their long-term clinical outcomes. I think that’s really where we can work closely with payers to make sure that patients are responding appropriately to these high-cost meds.
What are different examples of opportunities payers and academic centers can collaborate on?
I think 1 example of a way payers and manufacturers can collaborate is by a payer allowing a health system specialty pharmacy into their network and then by giving thresholds for the specialty pharmacy to be able to meet. Really, what that does is it holds the bar high so that patients are getting really good quality care, and then by providing this data back to the payer, they can use it for their analytics and benchmarking and be able to determine that patients are getting the best benefits and that the specialty pharmacy is doing a great job.
How does this collaboration, in turn, benefit patients?
What we found from patients that use our specialty pharmacy is that the satisfaction surveys are really good. We follow these patients really closely, make sure they’re doing well and not having any side effects, and managing those medications. The patients are really happy about that. We’re able to provide very personalized service. The patients meet the pharmacist face to face in clinic, they get phone calls as a follow-up from the pharmacist, and they’re very happy with it. We have very good satisfaction surveys that go to show that patients are happy with our service.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial
June 6th 2025Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and deletion of the 17p chromosome, with progression-free survival similar to patients without high-risk disease characteristics.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More